Business Context and Reporting Period
This Form 8-K filing by Big Rock Partners Acquisition Corp. (not NRX Pharmaceuticals, Inc.) covers events occurring on November 21, 2019. The registrant is a Special Purpose Acquisition Company (SPAC) incorporated in Delaware, trading on the NASDAQ under symbols BRPAU, BRPA, BRPAR, and BRPAW. The report details the results of a special meeting of stockholders held to vote on extending the deadline for consummating an initial business combination.
Key Financial Metrics and Liquidity
The filing does not provide standard operating financial metrics such as revenue, profit, or cash flow from operations, as the company is in a pre-business combination phase. Key liquidity and capital event figures include:
- Share Conversions: Holders of 919,091 shares exercised their right to convert shares into cash at approximately $10.59 per share, totaling approximately $9.7 million.
- Trust Account Deposit: Following the vote, the company deposited $0.02 per non-converted public share into its trust account, totaling $60,284.58 for the first monthly extension period.
- Warrant Exercise Price: Warrants are exercisable for one share of Common Stock at $11.50.
Material Changes and Corporate Actions
The primary material change reported is the approval of an amendment to the Company's certificate of incorporation to extend the deadline for consummating a business combination to March 23, 2020. Additionally, stockholders approved a proposal for the early winding up of the Company and redemption of 100% of outstanding public shares if the Board determines prior to the extended date that a business combination cannot be completed.
Voting results for the extension proposal were:
- For: 5,366,568
- Against: 99,901
- Abstain: 0
- Broker Non-Votes: 0
Outlook, Risks, and Management Commentary
Management has secured an extension to March 23, 2020, to complete a business combination. The filing indicates a conditional liquidity mechanism: the company must deposit additional funds into the trust account for up to three additional monthly extension periods if a combination is not consummated by December 23, 2019. The risk of liquidation remains if the Board determines a combination is unfeasible by the extended date, triggering the approved redemption of all public shares.
Investor Verification Checklist
- Verify the exact number of public shares outstanding post-conversion to calculate future trust deposit requirements.
- Confirm the status of the trust account balance following the $9.7 million redemption and the $60,284.58 deposit.
- Monitor the company's progress toward a business combination before the December 23, 2019, interim deadline to avoid further dilution or liquidation.
- Review the attached Exhibit 3.1 for specific terms of the charter amendment.